Olema Pharmaceuticals, Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2025. Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. The company has no products approved for commercial sale and has not generated any product revenue. Its business relies heavily on the development of its lead candidate, palazestrant (a dual CERAN/SERD for ER+/HER2- breast cancer), and its second candidate, OP-3136 (a KAT6 inhibitor).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(162.5) million | $(129.5) million |
| Research & Development Expenses | $157.7 million | $124.5 million |
| General & Administrative Expenses | $21.0 million | $17.7 million |
| Cash, Cash Equivalents, and Marketable Securities | $505.4 million | $434.1 million |
| Accumulated Deficit | $(597.6) million | $(435.1) million |
| Debt (Credit Facility Drawn) | $3.0 million | $0 |
| Net Cash Used in Operating Activities | $(146.7) million | $(104.4) million |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $33.0 million (25.5%) year-over-year, driven primarily by higher R&D spending.
- R&D Expense Growth: R&D expenses rose by $33.2 million, attributed to increased clinical operations for palazestrant and OP-3136, a $5.0 million increase in milestone payments to Aurigene, and higher personnel costs.
- Financing Activity: The company raised significant capital in late 2025, including a follow-on public offering in November 2025 yielding approximately $204.8 million in net proceeds. Additionally, the company drew $3.0 million under its amended Credit Facility.
- Interest Income: Interest income increased to $16.2 million from $12.7 million due to higher investment balances.
Guidance, Outlook, and Risks
Clinical Outlook:
- Palazestrant (OP-1250): The company is advancing two pivotal Phase 3 trials. OPERA-01 (monotherapy) expects top-line results in Fall 2026. OPERA-02 (combination with ribociclib) is enrolling, with top-line data expected in 2028.
- OP-3136: The Phase 1 clinical trial is enrolling, with initial clinical data expected in Q2 2026.
Liquidity: Management expects cash, cash equivalents, marketable securities, and the available credit facility balance to fund operations through mid-2028.
Key Risks:
- Capital Requirements: The company requires substantial additional capital to complete development and commercialization. Failure to raise funds could force delays or program eliminations.
- Clinical Uncertainty: There is no guarantee that palazestrant or OP-3136 will successfully complete clinical trials or obtain regulatory approval.
- Going Concern: The company has incurred losses since inception and expects to continue doing so for the foreseeable future, raising substantial doubt about its ability to continue as a going concern without additional financing.
- Third-Party Dependence: The company relies on third parties for manufacturing and clinical trial execution.
Investor Verification Checklist
- Verify the timeline and enrollment status of the OPERA-01 and OPERA-02 Phase 3 trials, as these are critical value drivers.
- Confirm the sufficiency of the $505.4 million cash position to fund operations through mid-2028, considering potential inflation or trial delays.
- Review the terms of the Novartis Collaboration regarding the supply of ribociclib for OPERA-02 and the potential repayment obligation of up to $275 million in the event of a change of control.
- Monitor upcoming milestone payments to Aurigene (up to $45 million remaining in development/regulatory milestones) and their impact on cash flow.
- Assess the progress of the OP-3136 Phase 1 trial and the timing of the expected Q2 2026 data readout.